Insider sale details
Mark Schoenberg, the Chief Medical Officer of UroGen Pharma Ltd, sold 7,373 ordinary shares of the company on February 3, 2026. The shares were disposed of at a price of $19.69 per share, resulting in a total transaction value of $145,174. The sale was carried out to meet withholding tax obligations associated with the settlement of restricted stock units.
Following the disposition, Schoenberg retains direct ownership of 144,985 shares of UroGen Pharma Ltd.
Recent financial performance
UroGen Pharma reported results for the third quarter of 2025 that fell short of market expectations on both primary metrics. Reported earnings per share were -$0.69, marginally below the forecast of -$0.68. Revenue for the quarter came in at $27.48 million, which was below the anticipated $33.19 million and represents a material shortfall relative to expectations.
These financial results have been a central focus for investors because the revenue miss was notably large. The company has not announced any mergers or acquisitions in recent developments, and there have been no reported analyst upgrades or downgrades following the earnings release.
Market and stakeholder context
Investors and other stakeholders continue to watch UroGen Pharma for further updates or strategic changes. The combination of an insider sale executed for tax purposes and a recent quarterly performance miss are among the developments being considered by market participants as they assess the companys current financial posture.
Because the sale was explicitly executed to address withholding tax tied to settled restricted stock units, the transaction reflects a tax-related liquidity event rather than an asserted change in managerial conviction expressed in the source material.
Summary takeaway
The factual record shows a tax-driven sale by UroGens CMO and a third-quarter 2025 earnings report that underperformed on both EPS and revenue. No additional corporate actions or analyst responses have been documented in the material provided.